OppenheimerFunds’s Sarepta Therapeutics SRPT Stock Holding History

OppenheimerFunds’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$91.6M	Buy	768,868 +641,904	+506%	+$82.5M	0.11%	188
2018 Q4	$13.9M	Buy	+126,964	New	+$15.9M	0.02%	595
2018 Q2	–	Sell	-501,058	Closed	-$37.1M	–	1823
2018 Q1	$37.1M	Sell	501,058 -909	-0.2%	-$60.6K	0.05%	395
2017 Q4	$27.9M	Buy	501,967 +96	+0%	+$5.09K	0.03%	477
2017 Q3	$22.8M	Buy	+501,871	New	+$20.1M	0.03%	525
2017 Q1	–	Sell	-104,350	Closed	-$2.86M	–	1890
2016 Q4	$2.86M	Buy	104,350 +310	+0.3%	+$12.5K	﹤0.01%	881
2016 Q3	$6.39M	Buy	+104,040	New	+$3.15M	0.01%	794
2013 Q4	–	Sell	-163,817	Closed	-$7.74M	–	952
2013 Q3	$7.74M	Sell	163,817 -392	-0.2%	-$15.1K	0.01%	757
2013 Q2	$6.25M	Buy	+164,209	New	+$5.87M	0.01%	754

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

OppenheimerFunds's SRPT Position: Q1 2019 in Review

OppenheimerFunds increased its Sarepta Therapeutics (SRPT) stake by 506% in Q1 2019, buying an estimated $82.5M and bringing the position to 768,868 shares worth $91.6M. The position accounts for 0.11% of the portfolio, ranked #188.

OppenheimerFunds first reported a position in SRPT in Q2 2013 and has held it in 9 quarters since. 371 funds tracked by Wall St. Rank hold SRPT as of Q1 2019.

OppenheimerFunds held 768,868 shares of Sarepta Therapeutics worth $91.6M as of Q1 2019.
OppenheimerFunds bought 641,904 Sarepta Therapeutics shares in Q1 2019, an estimated $82.5M.
Sarepta Therapeutics made up 0.11% of OppenheimerFunds's portfolio in Q1 2019, its #188 holding.
OppenheimerFunds first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 9 quarters since.
371 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.